{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:39:15Z","timestamp":1790807955674,"version":"4.1.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Mosquito-borne viral diseases are a group of viral illnesses that are predominantly transmitted by mosquitoes, including viruses from the Togaviridae and Flaviviridae families. In recent years, outbreaks caused by Dengue and Zika viruses from the Flaviviridae family, and Chikungunya virus from the Togaviridae family, have raised significant concerns for public health. However, there are currently no safe and effective vaccines available for these viruses, except for CYD-TDV, which has been licensed for Dengue virus. Efforts to control the transmission of COVID-19, such as home quarantine and travel restrictions, have somewhat limited the spread of mosquito-borne viral diseases. Several vaccine platforms, including inactivated vaccines, viral-vector vaccines, live attenuated vaccines, protein vaccines, and nucleic acid vaccines, are being developed to combat these viruses. This review analyzes the various vaccine platforms against Dengue, Zika, and Chikungunya viruses and provides valuable insights for responding to potential outbreaks.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1161149","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:37:16Z","timestamp":1683866236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Vaccine development for mosquito-borne viral diseases"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhiwei","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongliang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3390\/life11070615","article-title":"Flavivirus: from structure to therapeutics development","volume":"11","author":"Zhao","year":"2021","journal-title":"Life (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00146-8","article-title":"The global economic burden of dengue: a systematic analysis","volume":"16","author":"Shepard","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60233-6","article-title":"Rescuing the bottom billion through control of neglected tropical diseases","volume":"373","author":"Hotez","year":"2009","journal-title":"Lancet"},{"key":"B4","unstructured":"Dengue, chikungunya, zika incidence rate for subregions of the americas2022"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31450-2","article-title":"An update on zika virus infection","volume":"390","author":"Baud","year":"2017","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijid.2017.03.006","article-title":"Global expansion of chikungunya virus: mapping the 64-year history","volume":"58","author":"Wahid","year":"2017","journal-title":"Int J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.actatropica.2018.11.010","article-title":"Molecular epidemiology of dengue, yellow fever, zika and chikungunya arboviruses: an update","volume":"190","author":"Higuera","year":"2019","journal-title":"Acta Trop"},{"key":"B8","doi-asserted-by":"publisher","first-page":"112304","DOI":"10.1016\/j.biopha.2021.112304","article-title":"Targets and strategies for vaccine development against dengue viruses","volume":"144","author":"Wang","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52384","article-title":"Broadly neutralizing human antibodies against dengue virus identified by single b cell transcriptomics","volume":"8","author":"Durham","year":"2019","journal-title":"Elife"},{"key":"B10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.tim.2017.07.001","article-title":"Zika virus protease: an antiviral drug target","volume":"25","author":"Kang","year":"2017","journal-title":"Trends Microbiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1146\/annurev-immunol-042617-053142","article-title":"Immune response to dengue and zika","volume":"36","author":"Ngono","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41594-017-0010-8","article-title":"Structural biology of zika virus and other flaviviruses","volume":"25","author":"Hasan","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrmicro1928","article-title":"Architects of assembly: roles of flaviviridae non-structural proteins in virion morphogenesis","volume":"6","author":"Murray","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1505956112","article-title":"Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity","volume":"112","author":"Weiskopf","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature09555","article-title":"Glycoprotein organization of chikungunya virus particles revealed by X-ray crystallography","volume":"468","author":"Voss","year":"2010","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.05.007","article-title":"Crystal structure of chikungunya virus nsP2 cysteine protease reveals a putative flexible loop blocking its active site","volume":"116","author":"Narwal","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2021.1904004","article-title":"A review targeting the infection by CHIKV using computational and experimental approaches","volume":"40","author":"Kumar","year":"2022","journal-title":"J\u00a0Biomol Struct Dyn"},{"key":"B18","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","article-title":"Dengue infection","volume":"2","author":"Guzman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2017-000530","article-title":"Zika, chikungunya and dengue: the causes and threats of new and re-emerging arboviral diseases","volume":"3","author":"Paixao","year":"2018","journal-title":"BMJ Glob Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.03.007","article-title":"Original article dengue hemorrhagic fever - a systemic literature review of current perspectives on pathogenesis, prevention and control","volume":"53","author":"Wang","year":"2020","journal-title":"J Microbiol Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60572-9","article-title":"Dengue","volume":"385","author":"Guzman","year":"2015","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/vaccines8010063","article-title":"A review on dengue vaccine development","volume":"8","author":"Deng","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.108","article-title":"Development of the sanofi pasteur tetravalent dengue vaccine: one more step forward","volume":"33","author":"Guy","year":"2015","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.9.12739","article-title":"Development of sanofi pasteur tetravalent dengue vaccine","volume":"6","author":"Guy","year":"2010","journal-title":"Hum Vaccin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone","volume":"15","author":"Osorio","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1727697","article-title":"Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial","volume":"16","author":"Turner","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa346","article-title":"Characterization of the type-specific and cross-reactive b-cell responses elicited by a live-attenuated tetravalent dengue vaccine","volume":"223","author":"Michlmayr","year":"2021","journal-title":"J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30603-6","article-title":"Evaluation of a tetravalent dengue vaccine by serostatus and serotype","volume":"395","author":"Wilder-Smith","year":"2020","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the sanofi-pasteur CYD vaccine","volume":"15","author":"Whitehead","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2020.09.004","article-title":"Dengue vaccine development by the year 2020: challenges and prospects","volume":"43","author":"Wilder-Smith","year":"2020","journal-title":"Curr Opin Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw067","article-title":"A 12-Month-Interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response","volume":"214","author":"Durbin","year":"2016","journal-title":"J Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00931-13","article-title":"A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates","volume":"87","author":"Li","year":"2013","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.virusres.2014.07.017","article-title":"Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone","volume":"191","author":"Li","year":"2014","journal-title":"Virus Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840104","article-title":"Current development and challenges of tetravalent live-attenuated dengue vaccines","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.08.019","article-title":"Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects","volume":"26","author":"Guy","year":"2008","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"Randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","volume":"88","author":"Thomas","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the united states","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.19-0461","article-title":"Safety and immunogenicity of different formulations of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico: final results after 3 years of follow-up from a randomized, placebo-controlled phase I study","volume":"102","author":"Diaz","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"B43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/vaccines9020148","article-title":"mRNA vaccines against flaviviruses","volume":"9","author":"Wollner","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A novel lipid nanoparticle adjuvant significantly enhances b cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305227110","article-title":"Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells","volume":"110","author":"Weiskopf","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01424","article-title":"A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice","volume":"10","author":"Roth","year":"2019","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J Virol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1106318","article-title":"Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates","volume":"15","author":"Lam","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.101","article-title":"Preclinical and clinical development of a dengue recombinant subunit vaccine","volume":"33","author":"Manoff","year":"2015","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a phase I randomized clinical trial in flavivirus-naive adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602113","article-title":"Zika virus","volume":"375","author":"Petersen","year":"2016","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-006-0903-z","article-title":"Full-length sequencing and genomic characterization of bagaza, kedougou, and zika viruses","volume":"152","author":"Kuno","year":"2007","journal-title":"Arch Virol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12707","article-title":"Rapid spread of emerging zika virus in the pacific area","volume":"20","author":"Musso","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6508e1","article-title":"Zika virus infection among US pregnant travelers - august 2015-February 2016","volume":"65","author":"Meaney-Delman","year":"2016","journal-title":"Mmwr-Morbid Mortal W"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602412","article-title":"Zika virus infection in pregnant women in Rio de Janeiro","volume":"375","author":"Brasil","year":"2016","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre syndrome outbreak associated with zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33106-9","article-title":"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials","volume":"391","author":"Modjarrad","year":"2018","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah6157","article-title":"Protective efficacy of multiple vaccine platforms against zika virus challenge in rhesus monkeys","volume":"353","author":"Abbink","year":"2016","journal-title":"Science"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and immunogenicity of an anti-zika virus DNA vaccine","volume":"385","author":"Tebas","year":"2021","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708120","article-title":"Safety and immunogenicity of an anti-zika virus DNA vaccine - preliminary report","author":"Tebas","year":"2017","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0042-6822(02)00028-4","article-title":"Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus","volume":"306","author":"Chang","year":"2003","journal-title":"Virology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.3390\/vaccines9121464","article-title":"mRNA vaccine protects against zika virus","volume":"9","author":"Medina-Magues","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","article-title":"Modified mRNA vaccines protect against zika virus infection","volume":"169","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1602180","article-title":"Cutting edge: innate immune augmenting vesicular stomatitis virus expressing zika virus proteins confers protective immunity","volume":"198","author":"Betancourt","year":"2017","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01485-18","article-title":"A measles virus-based vaccine candidate mediates protection against zika virus in an allogeneic mouse pregnancy model","volume":"93","author":"Nurnberger","year":"2019","journal-title":"J Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01722-17","article-title":"Recombinant chimpanzee adenovirus vaccine AdC7-M\/E protects against zika virus infection and testis damage","volume":"92","author":"Xu","year":"2018","journal-title":"J Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02950-14","article-title":"Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors","volume":"89","author":"Abbink","year":"2015","journal-title":"J Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.049","article-title":"Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection","volume":"32","author":"Sharma","year":"2014","journal-title":"Vaccine"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1407466112","article-title":"Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag\/Tat-vaccinated rhesus macaques","volume":"112","author":"Carnathan","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.08.066","article-title":"Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1","volume":"34","author":"Cheng","year":"2016","journal-title":"Vaccine"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.05.021","article-title":"Zika virus vaccine: progress and challenges","volume":"24","author":"Shan","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4322","article-title":"A live-attenuated zika virus vaccine candidate induces sterilizing immunity in mouse models","volume":"23","author":"Shan","year":"2017","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41467-017-00737-8","article-title":"A single-dose live-attenuated vaccine prevents zika virus pregnancy transmission and testis damage","volume":"8","author":"Shan","year":"2017","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41467-018-02975-w","article-title":"Development of a chimeric zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2017.01.008","article-title":"Chikungunya virus","volume":"37","author":"Vu","year":"2017","journal-title":"Clin Lab Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-12-3075","article-title":"Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site","volume":"83","author":"Khan","year":"2002","journal-title":"J Gen Virol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3201\/eid1210.060495","article-title":"Chikungunya infection in travelers","volume":"12","author":"Hochedez","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.010736-0","article-title":"Evaluation of real-time nucleic acid sequence-based amplification for detection of chikungunya virus in clinical samples","volume":"58","author":"Telles","year":"2009","journal-title":"J Med Microbiol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.06.009","article-title":"Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy","volume":"99","author":"Thiberville","year":"2013","journal-title":"Antiviral Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.655743","article-title":"Co-Immunization with CHIKV VLP and DNA vaccines induces a promising humoral response in mice","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002142","article-title":"Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism","volume":"7","author":"Plante","year":"2011","journal-title":"PloS Pathog"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00104-16","article-title":"Vaccine and therapeutic options to control chikungunya virus","volume":"31","author":"Powers","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01970-16","article-title":"Mutation of the n-terminal region of chikungunya virus capsid protein: implications for vaccine design","volume":"8","author":"Taylor","year":"2017","journal-title":"mBio"},{"key":"B92","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/1743-422X-8-353","article-title":"Functional processing and secretion of chikungunya virus E1 and E2 glycoproteins in insect cells","volume":"8","author":"Metz","year":"2011","journal-title":"Virol J"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.045","article-title":"Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits","volume":"31","author":"Metz","year":"2013","journal-title":"Vaccine"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.07.072","article-title":"Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus","volume":"30","author":"Kumar","year":"2012","journal-title":"Vaccine"},{"key":"B95","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.virol.2016.01.009","article-title":"Next generation sequencing of DNA-launched chikungunya vaccine virus","volume":"490","author":"Hidajat","year":"2016","journal-title":"Virology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu114","article-title":"DNA Vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice","volume":"209","author":"Tretyakova","year":"2014","journal-title":"J Infect Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw111","article-title":"Rapid and long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against chikungunya virus","volume":"214","author":"Muthumani","year":"2016","journal-title":"J Infect Dis"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz202","article-title":"Immunogenicity and efficacy of a measles virus-vectored chikungunya vaccine in nonhuman primates","volume":"220","author":"Rossi","year":"2019","journal-title":"J Infect Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.069","article-title":"An adjuvanted adenovirus 5-based vaccine elicits neutralizing antibodies and protects mice against chikungunya virus-induced footpad swelling","volume":"37","author":"Dora","year":"2019","journal-title":"Vaccine"},{"key":"B100","doi-asserted-by":"publisher","first-page":"108021","DOI":"10.1016\/j.intimp.2021.108021","article-title":"Administration of COVID-19 vaccines in immunocompromised patients","volume":"99","author":"Negahdaripour","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a transformative technology for vaccine development to control infectious diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol Ther"},{"key":"B102","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendonca","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B103","doi-asserted-by":"publisher","first-page":"8870425","DOI":"10.1155\/2021\/8870425","article-title":"Comparison of immune response between SARS, MERS, and COVID-19 infection, perspective on vaccine design and development","volume":"2021","author":"Ansariniya","year":"2021","journal-title":"BioMed Res Int"},{"key":"B104","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"B105","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/v11010034","article-title":"Cytokine signature associated with disease severity in dengue","volume":"11","author":"Patro","year":"2019","journal-title":"Viruses"},{"key":"B106","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/tme.12658","article-title":"Coagulation abnormalities in dengue and dengue haemorrhagic fever patients","volume":"30","author":"Hassan","year":"2020","journal-title":"Transfus Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005738","article-title":"Dengue virus NS1 disrupts the endothelial glycocalyx, leading to hyperpermeability","volume":"12","author":"Puerta-Guardo","year":"2016","journal-title":"PloS Pathog"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0477-z","article-title":"A protective zika virus e-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection","volume":"20","author":"Slon-Campos","year":"2019","journal-title":"Nat Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/nri3916","article-title":"New insights into the immunopathology and control of dengue virus infection","volume":"15","author":"Screaton","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2015.06.057","article-title":"Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61273-9","article-title":"Zika virus: following the path of dengue and chikungunya","volume":"386","author":"Musso","year":"2015","journal-title":"Lancet"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2018.09.003","article-title":"A scoping review of chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control","volume":"188","author":"Silva","year":"2018","journal-title":"Acta Trop"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.076","article-title":"Status of research and development of vaccines for chikungunya","volume":"34","author":"Smalley","year":"2016","journal-title":"Vaccine"},{"key":"B116","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/v14050969","article-title":"A review on chikungunya virus epidemiology, pathogenesis and current vaccine development","volume":"14","author":"de Lima Cavalcanti","year":"2022","journal-title":"Viruses"},{"key":"B117","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12879-017-2894-7","article-title":"Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using Fc\u03b3R-expressing cells","volume":"18","author":"Ly","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-003814","article-title":"Novel vaccine safety issues and areas that would benefit from further research","volume":"6","author":"Salmon","year":"2021","journal-title":"BMJ Glob Health"},{"key":"B119","doi-asserted-by":"publisher","first-page":"10.1038\/d41586-020-01247-2","DOI":"10.1038\/d41586-020-01247-2","article-title":"Scores of coronavirus vaccines are in competition - how will scientists choose the best","author":"Callaway","year":"2020","journal-title":"Nature"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1161149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T04:37:21Z","timestamp":1683866241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1161149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":119,"alternative-id":["10.3389\/fimmu.2023.1161149"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1161149","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"article-number":"1161149"}}